Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of July 10, 2025 • 10:31 PM ET

Date/Time Source News Release
07/03/2025 04:30 PM EDT GlobeNewswire Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/26/2025 06:55 AM EDT GlobeNewswire Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
06/23/2025 08:00 AM EDT GlobeNewswire Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program
06/02/2025 08:00 AM EDT GlobeNewswire Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
05/15/2025 08:00 AM EDT GlobeNewswire Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update
05/12/2025 08:00 AM EDT GlobeNewswire Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May
05/06/2025 08:00 AM EDT GlobeNewswire Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate
05/05/2025 08:00 AM EDT GlobeNewswire Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision
04/08/2025 08:00 AM EDT GlobeNewswire Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
04/07/2025 08:00 AM EDT GlobeNewswire Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company's Transformation and Progress
Page

Additional News

As of July 10, 2025 • 10:31 PM ET

Date/Time Source News Release
10/22/2024 04:13 PM EDT SeekingAlpha Ocuphire Pharma acquires Opus Genetics
08/30/2024 08:00 AM EDT SeekingAlpha LENZ Therapeutics: Upcoming PDUFA, Strong Data, Some Risks
08/13/2024 09:10 AM EDT Zacks Ocuphire Pharma, Inc. (OCUP) Reports Q2 Loss, Lags Revenue Estimates
08/13/2024 08:48 AM EDT SeekingAlpha Ocuphire Pharma GAAP EPS of -$0.30, revenue of $1.11M
08/08/2024 08:55 AM EDT Zacks Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
08/06/2024 08:40 AM EDT Zacks Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates
05/11/2024 05:37 AM EDT US Earnings Reports Expected earnings - Ocuphire Pharma Inc.
05/10/2024 08:05 AM EDT SeekingAlpha Ocuphire Pharma GAAP EPS of -$0.29 misses by $0.20, revenue of $1.71M misses by $2.96M
05/09/2024 06:10 PM EDT Zacks The Beauty Health Company (SKIN) Reports Q1 Loss, Tops Revenue Estimates
03/09/2024 04:39 AM EST US Earnings Reports Expected earnings - Ocuphire Pharma Inc.
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.